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Abstract
Background: Despite the powerful impact in recent years of gene expression markers like the
green fluorescent protein (GFP) to link the expression of recombinant protein for selection of high
producers, there is a strong incentive to develop rapid and efficient methods for isolating
mammalian cell clones secreting high levels of marker-free recombinant proteins. Recently, a
method combining cell colony growth in methylcellulose-based medium with detection by a
fluorescently labeled secondary antibody or antigen has shown promise for the selection of
Chinese Hamster Ovary (CHO) cell lines secreting recombinant antibodies. Here we report an
extension of this method referred to as fluorescent labeling in semi-solid medium (FLSSM) to
detect recombinant proteins significantly smaller than antibodies, such as IGF-E5, a 25 kDa insulin-
like growth factor derivative.
Results: CHO cell clones, expressing 300 μg/ml IGF-E5 in batch culture, were isolated more easily
and quickly compared to the classic limiting dilution method. The intensity of the detected
fluorescent signal was found to be proportional to the amount of IGF-E5 secreted, thus allowing
the highest producers in the population to be identified and picked. CHO clones producing up to
9.5 μg/ml of Tissue-Plasminogen Activator (tPA, 67 kDa) were also generated using FLSSM. In
addition, IGF-E5 high-producers were isolated from 293SF transfectants, showing that cell selection
in semi-solid medium is not limited to CHO and lymphoid cells. The best positive clones were
collected with a micromanipulator as well as with an automated colony picker, thus demonstrating
the method's high throughput potential.
Conclusion: FLSSM allows rapid visualization of the high secretors from transfected pools prior
to picking, thus eliminating the tedious task of screening a high number of cell isolates. Because of
its rapidity and its simplicity, FLSSM is a versatile method for the screening of high producers for
research and industry.
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Background
Chinese Hamster Ovary (CHO) cells continue to be a
choice mammalian system for producing recombinant
biopharmaceuticals despite relatively low yields and high
costs. This is largely due to their ability to properly fold
and post-translationally modify complex recombinant
proteins such as antibodies for human administration [1-
3]. Advances in cell culture technologies, bioprocesses
and metabolic engineering have remarkably increased
yields of recombinant proteins produced by mammalian
cells [1,2,4]. Stable cell lines, employed for recombinant
protein production, are usually obtained by isolating and
characterizing high producers after transfection and ran-
dom integration of the gene of interest. Since the propor-
tion of high producers in the transfected cell pool is
extremely small, several methods have been designed to
facilitate their screening and selection [5].
"Blind" selection of high producers using limiting cell
dilution in 96 well plates after transfection, is a common
method. Following the formation of drug resistant colo-
nies, blind cloning requires amplifying and individually
testing hundreds (sometimes thousands) of these drug
resistant colonies or cell populations, most of which will
eventually be discarded as non/low producers. Although
the technique is well established and reliable, it is a labor-
intensive, time-consuming process. The advent of natural,
low toxicity fluorescent markers such as the Green Fluo-
rescent Protein (GFP) family opened a new era for
reporter genes and detection of recombinant protein
expression. Fluorescent markers are used in fusion pro-
teins, as co-expression indicators, or in dicistronic config-
uration to help visualize cells expressing the proteins of
interest within a mixed population [6-8]. High producers
can be isolated by using microscopy in conjunction with
micromanipulators [9], or with automated cell pickers, as
well as by fluorescence activated cell sorting (FACS)
[7,10]. Unfortunately, linking the production of a protein
of interest to expression of fluorescent markers means that
GFP or similar reporters will be present in the biomass/
culture medium, which is largely undesirable in the con-
text of biopharmaceuticals destined for human adminis-
tration. GFP can be replaced with a cell surface marker
normally absent in CHO cells, such as CD20, in order to
isolate high producers by FACS using a fluorescent anti-
body against the marker [11].
A different approach is to attempt at labeling the secreted
product itself, the main difficulty being to retain the prod-
uct around the cells in order to identify high producers.
This strategy can be traced back to the selection process for
myeloma mutants which involved plating the cells in
semi-solid medium containing agarose [12]. Their
method allowed not only immobilization of the cells to
form distinct clonal colonies but it also retained the
secreted antibodies in the immediate vicinity of cells.
When an anti-immunoglobulin overlay was added to the
semi-solid medium, a precipitate formed only around
positive colonies secreting antibodies. The method was
used extensively for hybridoma selection and eventually,
methylcellulose was found to be superior to agarose for
mammalian cell growth [13]. Over the last decade, the use
of single-cell gel matrices containing specific labels, has
been combined with flow cytometry to detect and sort
high secretors. Molten biotinylated agarose is used in con-
junction with avidin and a biotinylated capture antibody
against the recombinant protein [14]. Labeled cells are
sorted by flow cytometry once the cell suspension are
emulsified into small droplets. Cells can also be labeled
with biotin and conjugated with a capture antibody. The
accumulated recombinant protein is then visualized using
a second fluorescent antibody [15,16]. A disadvantage of
these methods is their complexity since a number of cap-
ture and labeling molecules are needed and that optimi-
zation of the labeling or growth condition may be
necessary. A variation of this approach is to coat the plates
directly with the capture molecule [17]. Recently, a
method combining cell colony growth in methylcellu-
lose-based medium with detection by unlabeled [18] or
fluorescently labeled secondary antibody or antigen [19]
has shown promise for the selection of cell lines secreting
recombinant antibodies. It is not clear however if such
method, that we referred to as Fluorescent Labeling in
Semi-Solid Medium (FLSSM), could be used to isolate
clones expressing proteins smaller than antibody mole-
cules, which are about 150 kDa.
In the present study, we demonstrate how FLSSM is used
to isolate CHO and 293SF cells secreting high-levels of
recombinant proteins other than antibodies. FLSSM was
compared to the traditional cell dilution in cluster wells to
isolate high producers of a small protein (25 kDa) derived
from the insulin like growth factor-1 (IGF-1). High pro-
ducers were isolated with FLSSM more rapidly and with
less effort. FLSSM was also used to isolate stable CHO cells
expressing Tissue Plasminogen Activator (tPA, 67 kDa). In
its simplest form, this method only requires a fluorescent
antibody against the secreted product, but it can also be
used with automated scanning and picking systems.
FLSSM is a versatile method for the screening of high pro-
ducers for research and industry.
Results
Isolation of clones secreting IGF-E5 using the conventional 
procedure
The structure of the recombinant IGF-1 protein (IGF-E5),
employed to compare the conventional procedure of
clone isolation (dilution in 96-well plate) with FLSSM,
appears in Fig. 1A. To generate stable CHO clones secret-
ing IGF-E5 using the conventional procedure, CHO cellsBMC Biotechnology 2009, 9:42 http://www.biomedcentral.com/1472-6750/9/42
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adapted to protein-free suspension culture were trans-
fected with a plasmid encoding IGF-E5 regulated by the
optimized cytomegalovirus (CMV) promoter [20], as well
as the hygromycin resistance gene. After transfection, the
cells were separated into 96-well plates in the presence of
hygromycin. Two to three weeks later, resistant cell popu-
lations from 419 wells were chosen and screened for IGF-
E5 expression by dot blot. To increase the odds that the
colonies originated from a single cell (a true clone), we
isolated cells only from plates containing less than 30
wells with resistant colonies. Despite this precaution,
some of the selected clones might have arisen from more
than one cell and therefore might not be true clones. The
selected populations with the highest levels of IGF-E5
were then further analyzed for IGF-E5 expression by west-
ern blot. From this experiment, equivalent cell numbers
were incubated for 7 days at 30°C. We and other groups
[21-24] have observed CHO cells have higher productivi-
ties at this temperature compared to the optimal growth
temperature (37°C). In the following text, all experiments
performed at 30°C are indicated. Equal supernatant vol-
umes were analyzed in this western blot. Using an anti-
body against the His Tag, a doublet migrating around 25
kDa was detected (Fig. 1B). The same bands were also
detected using an antibody against the murine IGF-1 indi-
cating that it corresponded to the IGF-E5 (data not
shown). The reason for the appearance of IGF-E5 as a dou-
blet is not known. The 4 best cell populations were 4-B4;
3-B4, 1-F3 and 7-E7 (Fig. 1B); 4-B4 was later compared to
the best clones obtained by FLSSM. For quantification, the
recombinant IGF-E5 was purified by affinity chromatog-
raphy on a nickel column and the amount of purified pro-
tein was determined using the Lowry assay (Fig. 1C). The
purified IGF-E5 was then used to make a standard curve
for quantification by spot blot (see below).
Selection of clones expressing IGF-E5 by FLSSM
To test if we could isolate high producer clones more effi-
ciently by direct labeling with a fluorescent antibody spe-
cific for the recombinant product, a pool of CHO cells
expressing IGF-E5 was generated as described above. Four-
teen days after electroporation and hygromycin selection,
the resistant cell pool was plated in semi-solid medium
containing a fluorescent anti-His Tag antibody. By micro-
scopic observation, about 5% of cells were associated with
a fluorescent signal (Fig. 2B and 2D). Control CHO cells,
secreting high levels of an unrelated product, showed no
fluorescent dots (Fig. 2F). From several wells of a 24-well
plate, 66 single cells or small colonies bearing fluorescent
dots under the microscope were picked from the semi-
solid medium with a micromanipulator (Caron et al
2000) and allowed to grow in a 96-well plate without
drug selection. The surviving 31 clones were first screened
by spot blotting 3-day old culture supernatants. Out of 31
clones, 25 showed detectable levels of IGF-E5 (Fig. 3A).
The five clones showing the strongest signal were seeded
at 5 × 105cells/ml and supernatants sampled at day 3 were
analyzed by quantitative spot blot. Production at 30°C
from the two best clones were then compared in a final
spot blot, with the starting pool as well as with the best
cell population (4-B4) obtained from the conventional
cloning method described above (Fig. 3B). The two best
clones isolated by FLSSM secreted 307 and 276 μg/ml
IGF-E5 respectively over 3 days, while 4-B4 (best by con-
Expression and purification of IGF-E5 Figure 1
Expression and purification of IGF-E5. A: Structure of 
IGF-E5. This recombinant protein was made by fusing the 
complete amino acid sequence of the murine IGF-1 to a His 
Tag (6H) and to an artificial peptide referred as E5-Coil. The 
latter possesses a strong affinity for a complementary pep-
tide, the K-Coil [34]. These peptides were designed to pro-
mote the interaction of protein containing E5-Coil and K-
Coil with each other. The secreted IGF-E5 is 152 amino acids 
in length. B: The same amount of supernatant of clones 
secreting IGF-E5 after 7 days of batch culture at 30°C were 
analyzed by western blot using an antibody against the His 
Tag. The clones were obtained using the conventional proce-
dure. Arrows: position of IGF-E5. Con: supernatant of non-
transfected CHO cells. Arrowhead: position of a minor pro-
tein component of unkown nature synthetized by some 
clones. C: Purification of IGF-E5 produced by clone 4-B4 by 
affinity chromatography on a nickel column. Unbounded pro-
tein fraction (i) and purified IGF-E5 (ii) were analyzed by 
SDS-PAGE and stained using the protein dye Coomassie 
Fluor Orange. The same protein fractions were also analyzed 
by western blot using an anti-His Tag antibody. Arrow: posi-
tion of IGF-E5. MW: position of molecular weight marker.
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ventional procedure) secreted 267 μg/ml. The starting cell
pool used for the FLSSM experiment had an IGF-E5 level
below the detection limit of the blot (data not shown).
Correlation of fluorescence intensities and secretion level
To confirm that the secreted recombinant protein levels
by the CHO-IGF-E5 clones correlated well with their fluo-
rescence intensities in semi-solid medium, we compared
the IGF-E5 secretion level and the fluorescence of seven
different clones under identical conditions. The clones
were plated in semi-solid medium for fluorescence scan-
ning and, in parallel, were cultured in liquid medium for
a 3-day batch assay at 30°C, followed by quantitative spot
blot analysis. Duplicate semi-solid medium wells for each
clone were scanned with a CellCelector™ (Aviso) and the
combined fluorescence for all colonies above threshold
were summated. Results (Table 1) show that the seven
clones ranked in the same order for production as for total
fluorescence intensity, with a correlation coefficient of
0.89.
CHO clones expressing tPA and 293SF expressing IGF-E5
To verify if clones producing a different recombinant pro-
tein could be isolated by FLSSM, a stable pool of CHO
cells expressing tPA (67 kDa), controlled by the CMV pro-
moter, was generated. The cells were then plated at low
density in semi-solid medium containing an antibody
against tPA labeled with Alexa488. The fluorescent signal
from positive CHO-tPA colonies was overall much
stronger than that from CHO-IGF-E5 positive cells.
Indeed, a precipitate around colonies was visible even in
phase contrast microscopy (Fig. 4A), as is the case when
the secreted product is itself an antibody [18]. From 32
positive cells and/or colonies picked, 8 showed strong
growth and they were analyzed by spot blot. Five of the
clones secreted more than 5 μg/ml (batch culture, 5 days,
30°C), with the best one at 9.5 μg/ml. These values are
very comparable with tPA-producing cell lines generated
by conventional methods in our laboratory (data not
shown).
To determine if our method could be extended to other
cell lines besides CHO, the human embryonic kidney
293SF cell line [25] was tested for colony formation in
semi-solid medium and for detection of IGF-E5 transfect-
ants. A stable pool of 293SF cells expressing IGF-E5 was
generated and they were subsequently plated in semi-
solid medium. Four days later, a liquid overlay containing
the fluorescent anti-His Tag antibody was added, and the
following day, the plates were scanned on a CellCelector™
automated cell picker. Despite the fact that the signal pro-
duced by the small 293-IGF-E5 colonies was relatively
weak (Fig. 4B), positive clones were easily detected. Six-
teen small colonies were picked and transferred by Cell-
Celector™ to a 96-well plate. Ten of the colonies survived
and they were tested by the same methods used for the
CHO-IGF-E5 clones. All tested 293-IGF-E5 clones secreted
significant amounts of IGF-E5. The best one produced 170
μg/ml after 5 days of batch culture at 30°C.
Discussion
In this work we have demonstrated that FLSSM works
equally well for detecting small and intermediate-sized
proteins, compared to large molecules such as antibodies.
We have shown that the method also worked for 293 cells.
A previous study [18] and application notes [19,26] have
indicated that this approach can be applied to isolate cells
secreting antibodies (about 150 kDa) or membrane asso-
ciated proteins. However our study is the first to demon-
strate that this method can be applied to smaller soluble
proteins such as IGF-E5 (25 kDa) and tPA (67 kDa).
Although we confirmed that FLSSM is amenable to
robotic high throughput operation using an automated
Detection of secreted IGF-E5 from stable CHO transfectants  by FLSSM Figure 2
Detection of secreted IGF-E5 from stable CHO 
transfectants by FLSSM. A, C and E: transmitted light 
images. B, D and F: green fluorescence at 510 nm from anti-
His Tag/FITC antibody present in semi-solid medium; fluo-
rescent dots formed by reaction of anti-His Tag/FITC with 
secreted IGF-E5 bearing His Tag moiety. A and B: longer 
exposure from single cell showing a cloud of fluorescent 
dots. C and D: positive CHO-IGF-E5 colony: signal is weak, 
but sufficient for detection of high producing cells. E and F: 
negative control; CHO cells secreting an unrelated product 
do not react with anti-His Tag antibody.
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cell picker such as the CellCelector™, this type of instru-
ment is not essential to isolate high producers on a
smaller scale. Indeed, this can be done as we have previ-
ously shown using a less sophisticated micromanipulator
[9]. Furthermore, colonies that are big enough (>0.5 mm)
and well dispersed inside a dish can be picked manually
with a simple micropipettor, making this method availa-
ble to virtually any laboratory.
Other methods that can isolate cell lines expressing solu-
ble and non-fluorescent recombinant proteins have been
described [5,14-17]. The challenge faced by these meth-
ods is to retain the secreted protein in the vicinity of the
producer cells. This can be done using various strategies
(cell biotinylation or biotinylated agarose in conjunction
with avidin and biotinylated capture antibodies, or coat-
ing the plates with a capture antibody). The major advan-
Screening and quantification of high-producing CHO-IGF-E5 clones by spot blot Figure 3
Screening and quantification of high-producing CHO-IGF-E5 clones by spot blot. A: initial screening of all colonies 
selected by FLSSM and picked by Quixell micromanipulator (A trough EE). std: 20 ng spot of purified IGF-E5 for reference. B: 
Quantitative spot blot. Top row: purified IGF-E5 standards, numbers indicate amounts spotted in nanograms. Bottom row: 2 
best clones isolated by FLSSM (L and Y) and best cell population isolated by classic dilution in wells (4-B4). Duplicates not 
shown. C: plot of the fluorescence signal obtained by scanning the standard spots using a Typhoon™ scanner, R2 = 0.99.
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Table 1: Correlation between cell colony fluorescence and recombinant protein secretion from CHO-IGF-E5 clones selected by 
FLSSM.
Clonea IGF-E5b 
production
SD
(N = 2)
Rankc 
production
Totald
Fluorescence.
Ranke
Fluorescence
L 1.00 0.16 1 1.00 1
V 0.46 0.10 2 0.90 2
A 0.24 0.04 3 0.30 3
W 0.12 0.01 4 0.28 4
F 0.10 0.02 5 0.26 5
J 0.07 0.01 6 0.17 6
E 0.08 0.00 6 0.11 7
aNames of stable CHO clones secreting various levels of IGF-E5 (Fig. 3A).
bProduction from a 3-day batch culture at 30°C was measured by quantitative spot blot against purified IGF-E5. The production was normalized to 
the highest producer (clone L).
cRank for IGF-E5 production (column 2) in decreasing order. Clones J and E were both assigned rank 6, because their production level was not 
significantly different.
dFluorescence was measured by scanning the wells at 510 nm using the CellCelector™. The fluorescence signal of all the colonies above 
background was summed and normalized to the highest value (clone L).
eRank for the total fluorescence (column 5) in decreasing order and independently from column 4.
FLSSM applied to different products and cell lines Figure 4
FLSSM applied to different products and cell lines. A, A' and C: transmitted light images. A and B: colonies from CHO-
tPA transfectant pool. B: detection of secreted tPA using an anti-tPA antibody conjugated to Alexa488 in semi-solid medium. 
Note the presence of positive and negative colonies in the same field. Arrow indicates positive, high-producing clone; A': insert 
blown up from A showing that a precipitate around the positive colony is visible in transmitted light microscopy. C and D: col-
ony from 293-IGF-E5 transfectant pool. D: detection of secreted IGF-E5 (small fluorescent dots at the colony periphery using 
an anti-His Tag antibody conjugated to FITC in semi-solid medium).
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tage of FLSSM over these methods, is its simplicity, since
only one fluorescent antibody is required for detection. As
we have shown, FLSSM is applicable to cells that are
adapted to suspension and serum free culture, the latter
point being important because of safety and regulatory
issues. An alternative technique used for selecting high
producer clones, which consists in direct labeling of cells
with a fluorescent antibody (without permeabilisation or
fixation) followed by flow cytometry analysis has been
described [27]. This method was tested on our strong
CHO-IGF-E5 (clone L) and on a parental CHO negative
control. Although we carefully followed the protocol
described in this article, no significant surface IGF-E5 was
detected when the antibody was used at the same concen-
tration as for FLSSM. When we increased the cell and anti-
body concentrations, a signal was detected but its
intensity was very weak (see additional file 1). It is not
clear why cells secreting IGF-E5 are difficult to label by
this method. Rapid diffusion of the molecule, due to its
small size (25 kDa) and/or poor retention of IGF-E5 on
the cell surface after secretion, could explain this observa-
tion. An added benefit of FLSSM is its ability to screen for
growth characteristics at the same time as high protein
production by analyzing the size of the colonie and the
intensity of the fluorescent signal. This method can also
be used to monitor clonal stability over time. A simple,
regular plating in semi-solid medium will easily reveal sig-
nificant drifts in homogeneity and intensity of the
secreted protein amongst the progeny of an original clone.
The recombinant IGF-E5 is a good test for this method
because of its relatively small size (25 kDa). We observed
that the fluorescent signal with IGF-E5 was significantly
weaker compared to that from tPA and an IgG (data not
shown). Many factors contribute to the intensity of the
detected signal: secreted product concentration, molecu-
lar size, shape, diffusion speed in methylcellulose, the
detection antibody's affinity for the secreted product and
the size of the colonies. The CHO-IGF-E5 positive cells
were picked early after plating as single cells or very small
colonies, which likely affected the survival rate of the
clones. Despite this weaker signal and the very small size
of the CHO-IGF-E5 colonies picked, several high CHO-
IGF-E5 producers were obtained by merely analyzing a
few dozen clones from FLSSM. In contrast, more than 400
cell populations had to be screened by the classic method
to find a similar producer. In addition, the relative fluores-
cence intensity of the CHO-IGF-E5 colonies in semi-solid
medium was proportional to the level of secretion of the
corresponding clones in batch culture, strongly support-
ing the notion that high-secretors are the brighter ones.
Our best CHO-tPA clone isolated by FLSSM produces 9.5
μg/ml of tPA in batch culture, which is significantly lower
than our best CHO-IGF-E5. This value however is compa-
rable to the best clones we characterized in our laboratory
using the standard dilution method (data not shown).
Although it is difficult to compare data obtained from dif-
ferent laboratories, our tPA production level is in the
range of those (10 to 30 μg/ml) reported in literature for
CHO cells in batch culture, without medium or growth
culture optimization [28,29].
It should be pointed out that the intensity of the fluores-
cent signal in FLSSM should only be used as a relative
index to compare different clones expressing the same
product in a particular host. Case in point, the fluorescent
signal surrounding CHO-tPA clones was much stronger
than the signal from CHO-IGF-E5 clones, even though the
best IGF-E5 clones were much higher producers. How-
ever, for a given cell host, secreted product and detection
antibody, the fluorescent signal should be proportional to
the level of expression, allowing isolation of the highest
producers from a mixed population.
We observed some toxicity (reduced growth and lack of
colony formation) when the cells were labeled with cer-
tain antibodies. Ideally, azide and thimerosal-free anti-
bodies should be used to minimize toxicity. These and
other potential contaminants present in commercial anti-
bodies can easily be removed by microdialysis. Even
though we have found that FLSSM allows detection of
high producers at the single cell level, it is more advanta-
geous and reliable to pick positive colonies of a minimal
size. Accordingly, conditions favoring good colony
growth should be optimized, such as medium composi-
tion, plating density and time of fluorescent antibody
addition. For 293SF-IGF-E5 selection, we saw that plating
cells in semi-solid medium without the detection anti-
body permitted initial colony growth. By adding the fluo-
rescent label in a liquid medium overlay 3–7 days later,
chances to successfully isolate high-producers improved.
Regardless of the cell selection method used, loss of
expression during clone amplification is always possible if
high-level recombinant protein expression is toxic and
negatively affects cell growth. To that effect it would be
advisable, if possible, to use an inducible, tightly-regu-
lated promoter (such as the Tetracycline-based system
[30] or the Cumate-based system [31] to drive the trans-
gene expression. A useful strategy would be to use an
inducible promoter in the "off' mode during cell colony
formation, and then add the inducer to reveal the high
producers for detection and picking. This should mini-
mize negative selection and favor stability of the high-
secretor clones. It has been shown that secreted product
detection is possible even with an un-labeled antibody
against the product [18]. Indeed, we have found that the
precipitate formed by the secreted product and the detec-
tion antibody around high-secretors is readily visible in
phase contrast or dark field microscopy.BMC Biotechnology 2009, 9:42 http://www.biomedcentral.com/1472-6750/9/42
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Conclusion
Fluorescence labeling in semi-solid medium (FLSSM)
allows rapid visualization of the high secretors from trans-
fected cell pools prior to picking, thus eliminating the
tedious task of screening a high number of cell isolates. It
can be used to select for growth characteristics at the same
time as high protein production. FLSSM should be appli-
cable for the isolation of most secreted protein producers,
provided that the product is secreted at a sufficient level
and that an antibody against it is available. It is far less
labor intensive than traditional methods and represents
large savings in time, supplies and incubator space. In
addition, the method has been tested successfully on
micromanipulator and robotic systems.
Methods
Plasmid construction
Restriction and DNA modifying enzymes were purchased
from New England Biolabs, Ltd (Pickering, Ont, Canada).
Plasmids were constructed using standard molecular biol-
ogy procedures and they were purified with the Qiagen
plasmid Maxi Kit (Qiagen, Valencia, CA). To construct
pMPG-IGF-E5, the coding sequence of IGF-1 was isolated
by PCR from the murine cDNA of that gene (GenBank ID:
BC012409, BF383724, ATCC, Manassas VA,) and primers
5'-ggatccggcaccatgtcgtcttcacacctc-3' and 5-ggtacctccacct-
gaaccggctgcttttgtaggcttc-3'. The PCR product was phos-
phorylated by treatment with T4 polynucleotide kinase
and cloned into the unique PmeI site downstream of the
CMV promoter of pMPGB34k, which was previously
digested with BamHI to remove the light chain of the B43
antibody [32]. pMPGB43k is an expression vector that car-
ries an enhanced version of the human CMV enhancer/
promoter [20] and a hygromycin resistance gene. The
DNA fragment encoding the His Tag and E5-Coil
sequence [33,34] was amplified by PCR using primers 5'-
tattggtaccggcgggcaccatc-3' and 5'-gcgaggtaccgctagcttattact-
tctcaagtgctg-3'. The PCR product was digested with KpnI
and cloned into the unique KpnI site downstream of the
IGF-1 sequence previously inserted into pMPGB43k. The
complete nucleotide sequence of IGF-E5 was confirmed
by DNA sequencing. Plasmid pMPG-tPA, encoding tissue
plasminogen (tPA) regulated by the CMV promoter and
hygromycin resistance, was constructed by isolating the
tPA cDNA by PCR from pETPFR (American Type Culture
Collection). A first amplification was performed using
primers AS1: 5'-gccgccaccatggatgcaatgaagaga-3' and AAS1:
5'-gttggatcctcacggtcgcatgttgtc-3' which inserted a Kozak
consensus sequence at the 5' end and a unique BamH1 at
the 3'end. A BamHI site was then added at the 5' end by
performing a second PCR reaction with primers AS2: 5'-
aacggatccgccgccaccatggatgca-3' and AAS1. The light chain
of B43 antibody from pMPGB43k was then replaced with
the PCR product by digestion with BamHI.
Cell culture
CHO cells adapted to serum-free suspension culture
(CHO-SF, Invitrogen, Grand Island, NY), were grown in
protein free chemically defined medium for CHO cells
(CD-CHO medium, Invitrogen) supplemented with 1×
HT supplement (Invitrogen), 4 mM glutamine and 50 μg/
ml dextran sulfate (MW: 500 000, Amersham Pharmacia
Biotech, Uppsala, Sweden). 293SF [25] were grown in
low-calcium-SFM (LC-SFM, Invitrogen, Grand Island, NY)
supplemented with 1% fetal bovine serum (HyClone,
Logan, Utah). Unless mentioned otherwise, all the cells
were grown at 37°C in the presence of 5% CO2.
Transfection and stable clone production
CHO-SF and 293SF were transfected by electroporation in
the presence of linearized plasmid using a BTX T820 elec-
trosquare porator (Genetronics, San Diego, CA) according
to the manufacturer's recommendations. For the clone
isolation using the "standard method", after electropora-
tion, the CHO-SF were diluted into growth medium and
incubated overnight in 6-well plates. The next day, they
were separated into 96-well plates (1000 and 3000 cells/
wells) in growth medium supplemented with 600 μg/ml
hygromycin B (Invitrogen). Resistant colonies, isolated
from plates in which less than 30 wells contained resistant
colonies to maximize the odds of isolating a true clone,
were then transferred to 24-well plates in the presence of
hygromycin B. Supernatant from confluent 24-well plates
were analyzed by dot blot for the presence of IGF-E5. To
generate clones using the FLSSM method (see below),
after electroporation, a pool of stable transfectants was
generated by growing the cells in the presence of 600 μg/
ml (CHO-SF) or 25 μg/ml (293SF) hygromycin B.
Cell plating in semi-solid medium
Immediately before plating in semi-solid medium, cells
were dispersed in a 35 mm Petri dish through a fine
microtip (Costar, Bethesda, MD) and observed under the
microscope. The process was repeated until only single
cells were observed. CHO-IGF-E5 and CHO-tPA stable
cell pools were mixed in medium containing Clonematrix
methylcellulose, XL Reagent (Genetix, Boston, MA) and
CDCHO-AGT 2× (Invitrogen), at a 1× final concentration
and supplemented with 8 mM L-glutamine (Invitrogen)
and fluorescent antibody (see below). 293SF-IGF-E5 sta-
ble cell pools were mixed in medium containing Clone-
matrix, 2× LC-SFM medium (1× final concentration),
1%FBS (HyClone) and 4 mM L-glutamine. The cells
(CHO and 29SF) were agitated and vortexed at medium
speed to ensure uniform distribution of all components
before plating. They were then seeded in 24-well dishes
(Sarstedt, Newton, NC) or 60 mm Petri dishes (Greiner,
Monroe, NC), made of untreated plastic, at densities of
500, 1000 and 2000 cells/m. After plating, the cells wereBMC Biotechnology 2009, 9:42 http://www.biomedcentral.com/1472-6750/9/42
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observed under the microscope to verify they were single
and well dispersed inside the dish.
Cell labeling and colony picking
Anti-His Tag-FITC antibody (Abcam, Cambridge, MA)
was used at 4 μg/ml to detect IGF-E5 secreting cells in
semi-solid medium. The anti-tPA (Cedarlane, Hornby,
Ont) antibody was first dialyzed on a microcon YM-50
spin filter (BioRad, Missisauga, ON) against PBS
(HyClone), and conjugated to Alexa488 fluorochrome
with a Microscale Protein Labeling Kit (Molecular Probes,
Eugene OR) according to the manufacturer's recommen-
dations. The labeled antibody was used at a concentration
of 1 μg/ml to detect tPA-secreting cells. Positive cells and
colonies were picked either with a Quixell micromanipu-
lator (Stoelting, Wood Dale, IL) using 50 μm glass capil-
laries, or with a CellCelector™ colony picker (Aviso, Jena,
Germany) equipped with the methylcellulose tool. For
Quixell picking, the most fluorescent cells were deter-
mined visually. For CellCelector picking, the plates were
scanned at 10× magnification and the brightest objects
were determined using the included analySIS software
(now called Cell D). Single cells and colonies were depos-
ited into 96-well dishes (Corning, Lowell, MA). Images of
fluorescently labeled cells were taken on a Leica DMIL
inverted microscope using a color 3CCD cooled camera
(Optronics, Goleta, CA) or a monochrome Retiga Exi
(QImaging, Surrey, BC) and Openlab software (Improvi-
sion, Coventry, England).
Analysis of protein production by dot blots and spot blots
For dot blot analysis, the culture supernatant was diluted
5 times with distilled water. The samples were denatured
by adding an equal volume of 2× lysis buffer (0.125 M
Tris-HCl pH 6.8, 4% SDS, 20% glycerol and 0.1%
bromophenol blue) and heated at 95°C for 5 min. The
samples were spotted on a nitrocellulose membrane
(Hybond-ECL, Amersham Biosciences Buckinghamshire,
UK) under vacuum on a dot-blot apparatus (Bio-Rad Lab-
oratories Canada Ltd., Mississauga, ON). The membrane
was incubated with an anti-His Tag antibody (Serotec,
Oxford, UK) followed by a horseradish peroxidase-conju-
gated anti-mouse IgG antibody (Amersham Biosciences).
The signal was revealed by chemiluminescence using the
ECL Western Blotting detection reagents (Amersham Bio-
sciences). For spot blot analysis [35] duplicate or triplicate
volumes of one microliter were spotted on nitrocellulose
membranes (Hybond-ECL) with a precision P2 micropi-
pette (Eppendorf, New York, NY). Quantitative spot blots
were made from batch samples, from clones seeded at 5 ×
105 cells/ml and grown for 3 days (CHO-SF) or 5 days
(293SF) under identical conditions at 30°C. At least three
dilutions were spotted for each clone to ensure that
detected values would fall in the linear domain of the
standard curve. IGF-E5 blots were treated with an anti-His
Tag antibody (Serotec) followed by an anti-mouse conju-
gated to Alexa488 (Invitrogen). tPA blots were treated
with a sheep anti-tPA primary antibody (Cedarlane) fol-
lowed by a rabbit anti-sheep antibody conjugated to Cy3
(Jackson, Immunoresearch Labs, West Grove, PA). Protein
standards (purified IGF-E5 or tPA (Calbiochem, San
Diego, CA)) were spotted in duplicate or triplicate serial
dilutions on each blot. The blots were scanned on a
Typhoon Trio+ fluorescence imager (Amersham Bio-
sciences) and analyzed by ImageQuant TL software
(Amersham Biosciences). The data was transferred to
Excel spreadsheets for standard curve plotting and result
interpolation.
Analysis of protein production by Western blot
Stable CHO transfectants (5.0 × 105) were resuspended
into 1 ml of growth medium in 24-well plates. The next
day, the plates were transferred to an incubator at 30°C
and incubated at this temperature for up to 14 days. At
selected time points, an aliquot of growth medium was
mixed with an equal volume of lysis buffer 2× supple-
mented with 5% β-mercaptoethanol. The samples were
heated for 5 min at 100°C and separated on a SDS-PAGE.
The proteins were transferred onto a nitrocellulose mem-
brane and the presence of the IGF-E5 was demonstrated
using anti-His Tag antibody by chemiluminescence as
described above.
Purification of IGF-E5
Actively growing CHO cells from clone 4-B4 (1.0 × 106/
ml) in a T-Flask were incubated at 30°C for 7 days. After
separation of supernatant and cells by centrifugation,
Complete protease inhibitor (Roche Diagnostics, Man-
nheim, Germany) and a final concentration of 10 mM
imidazole were added to the supernatant. The supernatant
was loaded onto a 5-ml HisTrap column (Amersham Bio-
sciences) using a peristaltic pump and the bound IGF-E5
was eluted with increasing concentrations of imidazole
(10 to 200 mM). The purified IGF-E5 was dialyzed against
PBS and concentrated on a centrifugal concentrator (Cen-
tricon YM-10, Millipore Corporation, Bedford, MA). After
determining the protein concentration with the DC pro-
tein assay (Bio-Rad laboratories, Hercules, CA), the puri-
fied IGF-E5 was stored at -80°C in 5% glycerol. The purity
of the protein was evaluated by SDS-PAGE followed by
staining with Coomassie Fluor™ Orange protein gel stain
(Molecular Probes, Eugene OR) and analyzed on a
Typhoon trio+ scanner (Amersham Biosciences). The
nature of the purified IGF-E5 was confirmed by Western
blot (as described above) using as primary antibody an
anti-His Tag antibody or a goat anti-IGF-1 antibody
(USBiological, Swampscott, MA).
Correlation of production and fluorescence in FLSSM
Seven CHO-IGF-E5 clones of various production levels
(as per initial spot blot screening) were seeded at 1.0 × 104
cells/ml in semi-solid medium containing anti His Tag-BMC Biotechnology 2009, 9:42 http://www.biomedcentral.com/1472-6750/9/42
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FITC antibody in duplicate wells of a PetriWell24 plate
(Genetix) and, in parallel batches at 1.0 × 106 cells/ml in
liquid growth medium. Duplicate wells of a 24-well dish
(Sarstedt, Montréal, QC) were incubated at 30°C for 3
days. Samples were clarified by centrifugation and ana-
lyzed by quantitative spot blot as described above. Semi-
solid medium plates were scanned on a CellCelector™
(Aviso). The product of area and mean fluorescence for all
the colonies above background threshold was determined
with the Cell D software (Aviso/Olympus) and summed
for each separate clone using an Excel spreadsheet. The
results were normalized to the brighest clone (L). Quanti-
tative spot blot results for batch production were normal-
ized to the highest producer (L).
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